ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
← catalyst calendarNCT05405595 · readout in 72 d
Sponsored by Adagene Inc (industry) · ADAG — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
186estimated
Sites
21
Countries
China, South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-15 | actual | When the study began enrolling |
| Primary completion | 2026-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-06-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced/Metastatic Solid Tumors
Interventions
- Drug: ADG126
- Drug: Pembrolizumab (KEYTRUDA®) — also filed as KEYTRUDA®
- Drug: Standard of Care (Trifluridine/Tipiracil-Bevacizumab) — also filed as Lonsurf and Avastin
- Drug: Standard of care (Fruquintinib) — also filed as Fruzaqla
Primary outcomes
what the primary-completion date above is the date OFMaximum tolerated dose (MTD) and RP2D for ADG126 in combination with pembrolizumab.
measured 9 months
the safety and tolerability of ADG126 at escalating dose level in combination with pembrolizumab in adults with advanced metastatic solid tumors
measured 9 months
Access the preliminary antitumor activity of ADG126-pembrolizumab combination regimens
measured 9 months
Maximum tolerated dose (MTD) and/or RP2D for ADG126 with Trifluridine/Tipiracil-Bevacizumab
measured 6 months
Access the preliminary antitumor activity of ADG126 with Pembrolizumab in combination standard of care
measured 6 months
Access and characterize the optimal dose based on safety and efficacy parameters
measured 9 months
Permalink · ADAG's whole pipeline · Catalyst calendar · Every registered study · What changed